Skip to main content

Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.

Publication ,  Journal Article
Armstrong, AJ; Carducci, MA
Published in: Curr Oncol Rep
May 2005

Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone for metastatic hormone-refractory disease. Although treatment is still considered palliative in nature, studies of chemotherapy for metastatic hormone-refractory prostate cancer (HRPC) have demonstrated improved overall survival compared with older regimens as well as clinically significant improvements in important endpoints, such as quality of life and time to progression. In particular, docetaxel has emerged as first-line therapy on an every-3-week schedule for metastatic HRPC, replacing mitoxantrone, as recently reported in the TAX327 trial. Docetaxel and estramustine combinations have the disadvantage of significant cardiovascular and gastrointestinal toxicity, and further use of estramustine is likely unwarranted as first-line therapy. Future trials examining novel biologic agents and combination therapies should use single-agent docetaxel as the reference standard. The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation.

Duke Scholars

Published In

Curr Oncol Rep

DOI

ISSN

1523-3790

Publication Date

May 2005

Volume

7

Issue

3

Start / End Page

220 / 227

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • Disease Progression
  • Clinical Trials as Topic
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., & Carducci, M. A. (2005). Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep, 7(3), 220–227. https://doi.org/10.1007/s11912-005-0077-y
Armstrong, Andrew J., and Michael A. Carducci. “Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.Curr Oncol Rep 7, no. 3 (May 2005): 220–27. https://doi.org/10.1007/s11912-005-0077-y.
Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep. 2005 May;7(3):220–7.
Armstrong, Andrew J., and Michael A. Carducci. “Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.Curr Oncol Rep, vol. 7, no. 3, May 2005, pp. 220–27. Pubmed, doi:10.1007/s11912-005-0077-y.
Armstrong AJ, Carducci MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Curr Oncol Rep. 2005 May;7(3):220–227.

Published In

Curr Oncol Rep

DOI

ISSN

1523-3790

Publication Date

May 2005

Volume

7

Issue

3

Start / End Page

220 / 227

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • Disease Progression
  • Clinical Trials as Topic
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis